The Acute Effects of Cocoa Flavanols Intake on Overt and Covert Attention

February 13, 2025 updated by: Oğuz Karataş, Konya Necmettin Erbakan Üniversitesi

The Acute Effects of Cocoa Flavanols Intake on Overt and Covert Attention: a Randomized, Double-blind Crossover Trial

The present study aimed to examine whether a cocoa beverage containing 710 mg of flavanols enhances both overt and covert attention in healthy young adults, using a randomized, double-blind, baseline- and placebo-controlled crossover design.

Study Overview

Detailed Description

Cocoa flavanols (CF) have various physiological effects that may directly or indirectly enhance cognitive functions. Following CF intake, a series of biochemical processes within vascular smooth muscle cells lead to the relaxation of smooth muscles, the dilation of blood vessels, and an increase in cerebral blood flow. For the brain to function optimally, cerebral blood flow must be maintained at a level that ensures a constant supply of oxygen and glucose to neurons. During periods of intense neuronal activity, neurons require more oxygen and nutrients, which is met by an increase in blood flow. Given that CF has been shown to enhance blood flow and perfusion in brain regions associated with attention (e.g., the parietal cortex, anterior cingulate cortex, and dorsolateral prefrontal cortex), it was hypothesized that CF intake could acutely improve both overt and covert attention.

Study Type

Interventional

Enrollment (Actual)

48

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Konya, Turkey, 42090
        • Konya Necmettin Erbakan University Cognitive Psychology Laboratuary

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Normal or corrected-to-normal visual acuity

Exclusion Criteria:

  • History of neurological, psychiatric, cardiovascular or metabolic disorders
  • Following a medically restricted diet
  • Taking antidepressant, anxiolytic, and antipsychotic drugs in the past three months
  • Currently taking anticoagulant
  • Taking herbal supplements in the past week
  • Allergic or intolerant to cocoa, caffeine, sucrose, or fructose
  • Color blindness

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Baseline/Placebo/Flavanol
Participants consumed sugar water, an alkalized cocoa beverage, and a natural cocoa beverage containing 710 mg of flavanols, with a one-week washout period between interventions.
Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
250 mL of hot water with 6 g of sugar
Experimental: Baseline/Flavanol/Placebo
Participants consumed sugar water, a natural cocoa beverage containing 710 mg of flavanols, and an alkalized cocoa beverage, with a one-week washout period between interventions.
Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
250 mL of hot water with 6 g of sugar
Experimental: Placebo/Baseline/Flavanol
Participants consumed an alkalized cocoa beverage, sugar water, and a natural cocoa beverage containing 710 mg of flavanols, with a one-week washout period between interventions.
Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
250 mL of hot water with 6 g of sugar
Experimental: Placebo/Flavanol/Baseline
Participants consumed an alkalized cocoa beverage, a natural cocoa beverage containing 710 mg of flavanols, and sugar water, with a one-week washout period between interventions.
Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
250 mL of hot water with 6 g of sugar
Experimental: Flavanol/Baseline/Placebo
Participants consumed a natural cocoa beverage containing 710 mg of flavanols, sugar water, and an alkalized cocoa beverage, with a one-week washout period between interventions.
Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
250 mL of hot water with 6 g of sugar
Experimental: Flavanol/Placebo/Baseline
Participants consumed a natural cocoa beverage containing 710 mg of flavanols, an alkalized cocoa beverage, and sugar water, with a one-week washout period between interventions.
Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
250 mL of hot water with 6 g of sugar

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spatial cueing task - accuracy
Time Frame: 1 hour 40 minutes post-ingestion
Difference in the total accuracy (%)
1 hour 40 minutes post-ingestion
Spatial cueing task - reaction time
Time Frame: 1 hour 40 minutes post-ingestion
Difference in the reaction time (ms) for correct responses
1 hour 40 minutes post-ingestion
Visual search task - accuracy
Time Frame: 1 hour 40 minutes post-ingestion
Difference in the total accuracy (%)
1 hour 40 minutes post-ingestion
Visual search task - reaction time
Time Frame: 1 hour 40 minutes post-ingestion
Difference in the reaction time (ms) for correct responses
1 hour 40 minutes post-ingestion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Oğuz Karataş, Ph.D., Konya Necmettin Erbakan University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 26, 2022

Primary Completion (Actual)

January 20, 2023

Study Completion (Actual)

January 20, 2023

Study Registration Dates

First Submitted

February 1, 2025

First Submitted That Met QC Criteria

February 1, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 13, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 122K636

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All IPD collected throughout the trial

IPD Sharing Time Frame

Beginning 3 months after publication with no end date.

IPD Sharing Access Criteria

A proposal that describes planned analyses must be submitted

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Young Adults

Clinical Trials on Flavanol

Subscribe